ArticleCell communication and signaling : CCS2011
Pro- and anti-apoptotic CD95 signaling in T cells.
Article in Cell communication and signaling : CCS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Pooled it
- Trial
- Respiratory syncytial virus inhibits type I interferon signaling to maintain HLA-DM expression in CD1ciScience · 2026Article
- Dynamic landscape of peripheral blood lymphocyte subsets in dengue patients: a multimodal single-cell and flow cytometry analysis.BMC infectious diseases · 2026Article
- Not so cold after all: tumor infiltrating CD8+ T cells in EBV-positive Burkitt lymphoma are quiescent, not exhausted.bioRxiv : the preprint server for biology · 2026Article
- Pre-existing CD95-based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD-L1 and TGFβ inhibition.Clinical and translational medicine · 2025Article
- Immune cell exhaustion and apoptotic markers in major depressive disorder: Effects of in vitro cannabidiol administration.Brain, behavior, & immunity - health · 2025Article
- Reproducible single-cell annotation of programs underlying T cell subsets, activation states and functions.Nature methods · 2025Article
- Two distinct subpopulations of human stem-like memory T cells exhibit complementary roles in self-renewal and clonal longevity.PLoS biology · 2025Article
- Distinct type 1 immune networks underlie the severity of restrictive lung disease after COVID-19.Nature immunology · 2025Article
- Article
- Reproducible single cell annotation of programs underlying T-cell subsets, activation states, and functions.bioRxiv : the preprint server for biology · 2024Article
- Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancer.Cell reports · 2024Article
- Tregs from human blood differentiate into nonlymphoid tissue-resident effector cells upon TNFR2 costimulation.JCI insight · 2024Article
- Long-term outcomes and immune profiling in children with multisystem inflammatory syndrome (MIS-C).Acta bio-medica : Atenei Parmensis · 2023Article
- An NKG2A biased immune response confers protection for infection, autoimmune disease, and cancer.Research square · 2023Article
- The abscopal effect of anti-CD95 and radiotherapy in melanoma.Discover oncology · 2023Article
- IL-27 shapes the immune properties of human astrocytes and their impact on encountered human T lymphocytes.Journal of neuroinflammation · 2022Article
- Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.Cell death & disease · 2022Review
- FAS receptor regulates NOTCH activity through ERK-JAG1 axis activation and controls oral cancer stemness ability and pulmonary metastasis.Cell death discovery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The TNF receptor superfamily member CD95 (Fas, APO-1, TNFRSF6) is known as the prototypic death receptor in and outside the immune system. In fact, many mechanisms involved in apoptotic signaling cascades were solved by addressing consequences and pathways initiated by CD95 ligation in activated T cells or other "CD95-sensitive" cell populations. As an example, the binding of the inducible CD95 ligand (CD95L) to CD95 on activated T lymphocytes results in apoptotic cell death. This activation-induced cell death was implicated in the control of immune cell homeostasis and immune response termination. Over the past years, however, it became evident that CD95 acts as a dual function receptor that also exerts anti-apoptotic effects depending on the cellular context. Early observations of a potential non-apoptotic role of CD95 in the growth control of resting T cells were recently reconsidered and revealed quite unexpected findings regarding the costimulatory capacity of CD95 for primary T cell activation. It turned out that CD95 engagement modulates TCR/CD3-driven signal initiation in a dose-dependent manner. High doses of immobilized CD95 agonists or cellular CD95L almost completely silence T cells by blocking early TCR-induced signaling events. In contrast, under otherwise unchanged conditions, lower amounts of the same agonists dramatically augment TCR/CD3-driven activation and proliferation. In the present overview, we summarize these recent findings with a focus on the costimulatory capacity of CD95 in primary T cells and discuss potential implications for the T cell compartment and the interplay between T cells and CD95L-expressing cells including antigen-presenting cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.